glp 1 intestine Intestinal GLP-1 and satiation: from man to rodents and back Actions of glucagon‐like peptide‐1 receptor

Each of these approaches has potential benefits and drawbacks, particularly in terms of risk for hypoglycemia, weight change, convenience, and side effects

We modeled an optimistic scenario using the best possible weight loss outcomes and long-term risk reductions, said first author Jennifer Hwang, DO, a primary care physician at UChicago Medicine

This approach delivers the peptide directly into the joint space, concentrating its effects at the site of cartilage damage, synovial inflammation, or tendon injury within the joint, rather than relying on systemic diffusion from a subcutaneous injection site

Coordinating with endocrinology to address the full spectrum of PCOS symptoms while using GLP-1 therapy produces better outcomes than treating weight in isolation

doi: 10.1186/s12937-016-0186-5 67